Sterling Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Sterling Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.55K	Sell	189 -94	-33%	-$2.85K	﹤0.01%	2668
2026 Q1	$8.6K	Buy	283 +22	+8%	+$586	﹤0.01%	2457
2025 Q4	$7.53K	Buy	261 +168	+181%	+$2.19K	﹤0.01%	2741
2025 Q3	$671	Hold	93	–	–	﹤0.01%	3134
2025 Q2	$923	Sell	93 -39	-30%	-$412	﹤0.01%	3074
2025 Q1	$1.25K	Sell	132 -37	-22%	-$514	﹤0.01%	2740
2024 Q4	$2.33K	Buy	169 +135	+397%	+$2.37K	﹤0.01%	2741
2024 Q3	$517	Buy	+34	New	+$168	﹤0.01%	2855

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sterling Capital Management's CAPR Position: Q2 2026 in Review

Sterling Capital Management reduced its Capricor Therapeutics (CAPR) stake by 33% in Q2 2026, selling an estimated $2.85K and leaving 189 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #2668.

Sterling Capital Management first reported a position in CAPR in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.6K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Sterling Capital Management held 189 shares of Capricor Therapeutics worth $4.55K as of Q2 2026.
Sterling Capital Management sold 94 Capricor Therapeutics shares in Q2 2026, an estimated $2.85K.
Capricor Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2668 holding.
Sterling Capital Management first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Capricor Therapeutics position peaked at $8.6K in Q1 2026.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.